Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)...

Details Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)... Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)...

2011-07-19

2011-07-19

Chung, Susannah (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S254090, C544S373000, C548S201000

Reexamination Certificate

active

07981894

ABSTRACT:
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine, crystaline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

REFERENCES:
patent: 5521241 (1996-05-01), Wu
patent: 5532241 (1996-07-01), Bottcher et al.
patent: 5723614 (1998-03-01), Bathe et al.
patent: 5977112 (1999-11-01), Bathe et al.
patent: 7381726 (2008-06-01), Bathe et al.
patent: 7834020 (2010-11-01), Bathe et al.
patent: 2009/0023749 (2009-01-01), Bathe et al.
patent: 0648767 (1995-04-01), None
patent: 0738722 (1996-10-01), None
patent: 0072832 (2000-12-01), None
patent: 02006153 (2002-09-01), None
Remington Farmacia Tomo 2 19a edición.
Farmacotecnia Teorica Y Practica Tomo IV, Dr. José Heiman.
Hungarian Search Report of May 10, 2010 citing HU P0201275 which corresponds to WO 00/72832.
Sorbera, L.A., et al. “Vilazodone Hydrochloride. Antidepressant 5-HT1APartial Agonist 5-HT Reuptake Inhibitor” Drugs of the Future 2001, 26(3):247-252 (Mar. 2001).
Summary of Facts Regarding US Clinical Trials Prior to Jun. 5, 2001.

Affiliated with

Also associated with

Rating

Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2686063